Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.

INTRODUCTION: The coronavirus 2019 disease (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to health care workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal and review of key documents identified by the Cardiac Society of Australia and New Zealand Board and Council members, the Australian and New Zealand Society of Cardiac and Thoracic Surgeons, and key cardiology, surgical and public health opinion leaders. MAIN RECOMMENDATIONS: Common acute cardiac manifestations of COVID-19 include left ventricular dysfunction, heart failure, arrhythmias and acute coronary syndromes. The presence of underlying CVD confers a five- to tenfold higher case fatality rate with COVID-19 disease. Special precautions are needed to avoid viral transmission to this population at risk. Adaptive health care delivery models and resource allocation are required throughout the health care system to address this need. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: Cardiovascular health services and cardiovascular health care providers need to recognise the increased risk of COVID-19 among CVD patients, upskill in the management of COVID-19 cardiac manifestations, and reorganise and innovate in service delivery models to meet demands. This consensus statement, endorsed by the Cardiac Society of Australia and New Zealand, the Australian and New Zealand Society of Cardiac and Thoracic Surgeons, the National Heart Foundation of Australia and the High Blood Pressure Research Council of Australia summarises important issues and proposes practical approaches to cardiovascular health care delivery to patients with and without SARS-CoV-2 infection.

2023 position statement on improving management for patients with heart failure in Aotearoa New Zealand.

Heart failure affects 1-3% of the population and remains a major public health problem, with high rates of hospitalisation and mortality. Health inequities in the incidence of heart failure have widened over the last 13 years in Aotearoa New Zealand. Urgent action is required to address the inequitable burden of heart failure among Maori and Pasifika. Regional and international heart failure guidelines now provide clear and consistent guidance on the contemporary approach to management for patients with heart failure. The purpose of this position statement is to ensure that all people in Aotearoa New Zealand have access to optimal healthcare delivery and pharmacotherapy for contemporary management of heart failure. Three main areas are addressed, including: 1) access to evidence-based pharmacotherapy for patients with heart failure, 2) the importance of early initiation and titration of pharmacotherapy, and 3) the workforce required to ensure timely delivery of heart failure therapies. Implementation of evidence-based healthcare will ensure all patients with heart failure in Aotearoa New Zealand have opportunity for substantial improvement in health.

Clinical trial participation improves outcome: a matched historical cohort study.

BACKGROUND: Well-conducted, investigator-led randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy of new treatments and are a key component of evidence-based medicine. It is unclear whether participating in an RCT is beneficial to the individual before the results of RCTs are known. PURPOSE: In a matched historical cohort study, we examined whether participation in RCTs was associated with improved health outcomes. METHODS: Participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET), or Telmisartan Randomized Assessment Study in ACE-intolerant Subjects with Cardiovascular Disease (TRANSCEND) studies and non-participant controls were selected from patients attending outpatient clinics at Middlemore Hospital between 2001 and 2003. RESULTS: A total of 251 RCT participants and 502 randomly selected patients not enrolled in a trial but who met study entry criteria were matched for age, gender, and ethnicity. There was a significant difference in all-cause mortality for trial participants versus non-participants over the study period (unadjusted relative risk reduction (RRR) = 63%; 95% confidence interval (CI) = 28%-81%) and a significant reduction in cardiovascular mortality (unadjusted RRR = 81%; 95% CI = 17%-95%) favouring RCT participants. Allowing for co-morbidity, the adjusted RRR of all-cause mortality associated with trial participation was 55% (95% CI = 10%-77%). Active treatment in an RCT was found to be less explanatory than trial participation. The adjusted RRR for cardiovascular mortality associated with active treatment in a trial was 86% (95% CI = -2% to 98%), with trial participation found to be less explanatory than active treatment. LIMITATIONS: The main limitations of this trial relate to its design as a retrospective study with a historical cohort comparison group. Limitations include lack of complete data for some patients, bias in selection of the comparison group, and the effects of confounding variables. However, the study design and analysis were planned so as to minimize these as much as possible. CONCLUSION: This study revealed significantly lower all-cause mortality among participants in industry-sponsored RCTs compared with non-participants who received routine hospital outpatient care. This effect was independent of study drug.

An uncommon complication of infective bacterial endocarditis.

Coronary artery septic embolisation resulting in cardioembolic myocardial infarction (MI) is a rare complication of bacterial infective endocarditis (IE), representing <1% of complications related to IE. Diagnosis requires a combination of high clinical suspicion, coronary angiography, echocardiography and cultures of peripheral blood and/or embolic material. The associated mortality rate remains high despite early diagnosis. Optimal interventional therapy is unknown with published international experience over the past two decades limited to very small case series and individual case reports. We present a case of ST elevation MI resulting from coronary artery septic embolisation with an accompanying comprehensive review of the literature.

Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction.

After ST-elevation myocardial infarction, the association between left ventricular sphericity (measured by biplane ventriculography) and survival rate at a median of 6.5 years was determined in 825 patients. The highest tertile of sphericity (vs the lowest and middle tertiles) was associated with a decreased 10-year survival rate in patients who had anterior myocardial infarction (p = 0.002), inferior myocardial infarction (p = 0.011), Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow (p = 0.005), or TIMI grade 0 to 2 flow (p = 0.001) in the infarct artery. The independent multivariate predictors of a 10-year survival rate were ejection fraction (p = 0.002), treadmill exercise duration (p = 0.004), biplane left ventricular sphericity index (p = 0.032), age (p = 0.043), and end-systolic volume index (p = 0.047), but not TIMI flow grade.

Monitoring change in the three-dimensional shape of the human left ventricle.

BACKGROUND: Characterizing left ventricular (LV) remodeling after myocardial infarction or LV shape change resulting from LV shape-restoration operation can yield valuable prognostic information. However, current methods measure only global parameters of LV shape. METHODS: We developed and validated a method for measuring change in regional LV shape by aligning a patient's follow-up 3-dimensional LV surface reconstruction to baseline surface. We tested the diagnostic power of 6 distance functions to detect a known shape deformation. To create the test data, the LV endocardial surface of a control subject was reconstructed using 3-dimensional echocardiographic techniques. The surface was deformed 9 different ways to model LV dilation (3 different locations and severities). Normal shape variability was defined from 18 serial studies of 6 control subjects. The severity of regional dilation was computed as the orthogonal distance between the aligned baseline and deformed LV surfaces. Deformation was quantified according to regional location using the 16-segment map of the LV. RESULTS: Normal LV shape variability was 3.38 mm. The LV deformations ranged from 2.95 to 8.02 mm. Gaussian distance function produced the highest accuracy for measuring deformation distances (P <.005 by analysis of variance). In addition, the gaussian function correctly identified the location of the maximum deformation in 6 of the 9 distorted surfaces. In the 3 remaining surfaces, the gaussian alignment selected an adjacent basal segment with a similar deformation distance (mean error: 0.2 +/- 0.17 mm). The gaussian function's accuracy in pinpointing the deformation equaled or exceeded the performance of the other 5 functions tested. CONCLUSION: This new method of aligning 3-dimensional LV surfaces in space facilitates detecting, measuring, and localizing regional shape change in the human LV independent of anatomic landmarks or geometric references. Potential applications include quantitative monitoring of change in regional LV shape after a pathologic process and/or surgical procedure to document efficacy of treatment and to assess prognosis.

Increased B-type natriuretic peptide is associated with an abnormal blood pressure response to exercise in asymptomatic aortic stenosis.

AIMS: Both raised plasma levels of B-type natriuretic peptide (BNP) and an abnormal exercise response predict adverse clinical outcomes in aortic stenosis (AS). This study examines the relationship between the response to treadmill exercise and plasma levels of BNP in AS. METHODS AND RESULTS: 34 asymptomatic patients with moderate or severe AS (mean valve area 0.96+/-0.3 cm(2)) and 15 age matched controls underwent echocardiography, treadmill exercise testing, and BNP analysis. Compared to control subjects, AS patients had a higher left ventricular mass index, (133+/-50 vs 106+/-24 g/m(2), p=0.03), higher E/E' ratio, (10.6+/-3.6 vs 6.7+/-1.8, p=<0.0001), higher ejection fraction, (65+/-6 vs 59+/-6%, p=0.03), elevated resting BNP (11.4+/-6.5 vs 7.4+/-4.0 pmol/L, p=0.03) and shorter exercise duration (8.2+/-3.0 min vs 10.9+/-2.6 min, p=0.002). AS patients with an increase in systolic BP of 20 mmHg (13.8+/-6.1 vs 8.6+/-6.0 pmol/L, p=0.003). The BNP measured at peak exercise was also associated with the BP response (p=0.003). The area under the receiver operator curve to predict an abnormal BP response to exercise was 0.82 for BNP measured at rest but only 0.46 for aortic valve area. There was a modest association between raised BNP and lower exercise capacity. CONCLUSION: In patients with AS there is an association between BNP and an abnormal BP response to exercise. Further study is needed to determine the incremental prognostic value of BNP and exercise testing in asymptomatic AS.

Reliability of echocardiographic indices of dyssynchrony.

BACKGROUND: Echocardiographic indices of dyssynchrony are increasingly used to select candidates for cardiac resynchronization therapy. For widespread screening of heart failure patients, such variables need to be comparable when evaluated by different operators using different equipment. OBJECTIVE AND METHODS: To evaluate the reproducibility and obtainability of echocardiographic indices of mechanical dyssynchrony, we studied 40 subjects stratified according to QRS morphology and systolic function. Two echocardiograms were performed on each patient by different sonographers on different machines and each study was analyzed by two observers. RESULTS: All blood-pool and tissue Doppler indices of dyssynchrony were obtainable in over 97% of cases. Blood-pool Doppler measures were the most reproducible indices of intraventricular dyssynchrony (aortic ejection delay) and interventricular dyssynchrony (aortopulmonary difference in ejection delay). For annular tissue Doppler delays, the time to peak velocity was consistently more reproducible than the time to velocity onset. CONCLUSION: Differences in the reliability of echocardiographic indices may affect their suitability as screening tests for dyssynchrony.

Longitudinal left ventricular contractile dysfunction after exercise in aortic stenosis.

OBJECTIVE: To determine whether longitudinal left ventricular systolic function measured by Doppler tissue imaging (DTI) after exercise can identify early left ventricular dysfunction in asymptomatic patients with moderate-severe aortic stenosis. DESIGN: Case-control study. SETTING: Outpatient cardiology departments. PATIENTS: 20 patients with aortic stenosis, with or without equivocal symptoms, a peak aortic valve velocity > or =3 m/s, and left ventricular ejection fraction >50% and 15 aged-matched normal controls. INTERVENTIONS: Echocardiogram performed at rest and immediately after treadmill exercise. MAIN OUTCOME MEASURES: The peak systolic velocity of the lateral mitral annulus (S') by DTI at rest and immediately after exercise, exercise capacity, exercise systolic blood pressure and the plasma level of B-type natriuretic peptide (BNP). RESULTS: For patients with aortic stenosis, mean (SD) aortic valve area was 0.95 (0.3) cm(2). At rest, S' was similar for patients with aortic stenosis and controls, respectively (8.5 (1.5) vs 9.1 (1.8) cm/s, p = 0.15). However, after exercise, S' (12.2 (3.2) vs 17 (2.8) cm/s, p<0.001) and the increase in S' between rest and exercise (4 (3) vs 7.9 (1.5) cm/s, p<0.001) were lower in patients with aortic stenosis. In patients with aortic stenosis, a smaller increase in S' after exercise was associated with lower exercise capacity (r = 0.5, p = 0.02), a smaller increase in exercise systolic blood pressure (r = 0.6, p = 0.005) and higher plasma level of BNP (r = 0.66, p = 0.002). CONCLUSION: In asymptomatic patients with moderate-severe aortic stenosis a lower than normal increase in peak systolic mitral annular velocity after treadmill exercise is a marker of early left ventricular systolic dysfunction.

Rapid and accurate left ventricular surface generation from three-dimensional echocardiography by a catalog based method. Rapid LV surface generation by three-dimensional echo.

BACKGROUND: Quantitative analysis from three-dimensional (3D) echocardiography requires accurate reconstruction of left ventricular (LV) surfaces. This currently requires time-consuming manual image tracing. We describe and validate an alternative rapid method of generating LV surfaces. METHODS: A 3D-image set is acquired using transthoracic scanning. Images from five standard echo views are displayed and border points selected where anatomic landmarks are well defined. A LV surface is reconstructed as a convex weighted sum of LVs from a catalog of 80 LVs. The intersections of the surface with the five views are presented on these images. The routine may be rerun until the LV surface matches the images. One LV surface is generated in 3 min +/- 27 s. In 41 studies (19 normal, 15 previous infarction, seven cardiomyopathy) the volumes of the catalog-fit endocardial and epicardial surfaces were compared with volumes from surfaces reconstructed from full manual tracing. RESULTS: Over a wide range of LV volumes and ejection fraction (EF), the catalog-fit results correlated closely to those from manual tracing: end-diastolic volume (194 +/- 99 vs. 204 +/- 110 ml, y = 0.93x, R2 = 0.99, SEE = 19 ml, p < 0.001), end-systolic volume (122 +/- 95 vs. 131 +/- 106 ml, y = 0.92x, R2 = 0.99, SEE = 13 ml, p < 0.001), EF (42 +/- 16 vs. 42 +/- 15%, y = x, R2 = 0.99, SEE = 4%, p < 0.001) and mass (220 +/- 88 vs. 204 +/- 86 g, y = 1.1x, R2 = 0.99, SEE = 24 g, p < 0.001). The endocardial catalog surface was generated from an average of 20 points and three computational runs for both end-diastole and end-systole. CONCLUSIONS: The catalog method of LV reconstruction from 3D-echo provides accurate measurement of volume, EF and mass. The speed of the method is a major advantage.

Three-dimensional assessment of two-dimensional technique for evaluation of right ventricular function by tricuspid annulus motion.

BACKGROUND: Measurement of tricuspid annulus motion (TAM) is an easy way to estimate right ventricular ejection fraction (RVEF). However the accuracy of two-dimensional (2-D) methods for analyzing the three-dimensional (3-D) structure of the tricuspid annulus has not been evaluated. OBJECTIVE: This study evaluated the accuracy with which 2-D measurements of TAM reflect RVEF using 3-D reconstructions of the heart at end diastole (ED) and end systole (ES). METHODS: 2-D echocardiographic studies were performed on 12 subjects and used to reconstruct the RV and tricuspid annulus in 3-D at ED and ES. Measurements of TAM from medial and lateral positions on the annulus were selected from the standard echocardiographic apical four-chamber view. The minimum and maximum possible TAM values, RV volumes, and movement of the apex of the heart along the trajectory of TAM were calculated from the 3-D reconstructions. RESULTS: TAM correlated highly with RVEF (r > or = 0.90). Values found by 2-D and 3-D techniques were not significantly different. Correcting TAM for apex motion did not improve correlation. Summation of medial and lateral TAM data increased correlation values slightly relative to lateral TAM alone. Regional aberrant contractility degraded the predictive value of TAM. CONCLUSION: Estimation of RVEF from 2-D echo measurement of TAM is accurate, especially when medial and lateral TAM are summed, except in patients with severe apical RV dysfunction.